Huawei plans more AI pharma partnerships, mainly with Chinese drugmakers

Huawei intends to sign more AI partnerships with pharmaceutical companies, according to William Zhang, president of its healthcare business unit, who told Reuters the projects currently run mainly with domestic Chinese drugmakers. The company sells compound screening tools alongside its Ascend and Kunpeng chips, the same domestic stack it has been building out since US […]
This story continues at The Next Web